Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

26.5%

157 terminated/withdrawn out of 592 trials

Success Rate

67.2%

-19.4% vs industry average

Late-Stage Pipeline

1%

6 trials in Phase 3/4

Results Transparency

73%

233 of 321 completed trials have results

Key Signals

68 recruiting233 with results123 terminated34 withdrawn

Enrollment Performance

Analytics

Phase 2
236(44.3%)
Phase 1
175(32.8%)
N/A
92(17.3%)
Early Phase 1
24(4.5%)
Phase 3
6(1.1%)
533Total
Phase 2(236)
Phase 1(175)
N/A(92)
Early Phase 1(24)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (592)

Showing 20 of 592 trials
NCT06411691Phase 1Recruiting

KRAS-Targeted Vaccine Combined With Balstilimab and Botensilimab for Patients With Stage IV MMR-p Colorectal Cancer and Pancreatic Ductal Cancer

Role: lead

NCT07734870Phase 2Not Yet Recruiting

Tirzepatide for Treatment of CCCA

Role: collaborator

NCT05950139Phase 1Recruiting

Peptide Vaccine To Prevent Acquired Resistance In Patients With Advanced ALK+ NSCLC

Role: lead

NCT07424222Phase 1Recruiting

Ruxolitinib for Immune Effector Cell Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (RISE)

Role: lead

NCT07140315Phase 1Recruiting

DK222 Study at Hopkins

Role: lead

NCT07580339Phase 2Not Yet Recruiting

Combining DCSZ11 With Radiation and Chemotherapy as Neoadjuvant Treatment for pMMR Locally Advanced Rectal Cancer

Role: lead

NCT04117087Phase 1Active Not Recruiting

Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected Mismatch Repair Protein (MMR-p) Colorectal and Pancreatic Cancer

Role: lead

NCT06014255Phase 2Active Not Recruiting

Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer

Role: lead

NCT07062549Phase 1Recruiting

Study of 111In-XYIMSR-01 SPECT/CT in Patients With Metastatic Clear Cell Renal Cell

Role: lead

NCT04447651Active Not Recruiting

Patient Response to Immunotherapy Using Spliceosome Mutational Markers (PRISMM)

Role: lead

NCT07281768Phase 2Recruiting

Capecitabine/Oxaliplatin Chemotherapy and Cemiplimab With or Without Fianlimab or REGN7075 in Locally Advanced Rectal Cancer

Role: lead

NCT06463249Not ApplicableActive Not Recruiting

Behavioral Weight Loss for Cancer Survivors in Maryland: A Trial With Adaptive Interventions

Role: lead

NCT04363164Phase 2Recruiting

Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression

Role: lead

NCT06796543Not ApplicableRecruiting

Targeted Oligometastatic Radiation in Pediatric and Young Adult Patients With Soft Tissue and Bone Sarcoma

Role: lead

NCT04465643Phase 1Completed

Neoadjuvant Nivolumab Plus Ipilimumab for Newly Diagnosed Malignant Peripheral Nerve Sheath Tumor

Role: lead

NCT02743910Completed

Monitoring Plasma Tumor DNA in Early-Stage Breast Cancer

Role: lead

NCT03114865Phase 1Active Not Recruiting

A Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission Maintenance

Role: lead

NCT03603002Not ApplicableCompleted

Pathologic and Immunologic Response After Ablative Radiation in Lung Cancer

Role: lead

NCT04131413Phase 1Recruiting

HPV DNA Vaccine Via Electroporation for HPV16 Positive Cervical Neoplasia

Role: lead

NCT02422641Phase 2Recruiting

Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis

Role: collaborator